急性心肌梗死后β受体阻滞剂的应用进展被引量：12

下载PDF

导出

摘要急性心肌梗死（AMI）的治疗在不断进步,从最初的单纯药物治疗,到溶栓和急诊经皮冠状动脉介入（PCI）术的再灌注治疗,其中β受体阻滞剂一直是治疗AMI的重要药物,目前指南强调无禁忌证者应在24h内口服β受体阻滞剂,并在住院期间以及出院后持续使用;对最初有禁忌证者,住院期间应重新评估能否使用[1-2],但近期有Meta分析[3]对指南提出了质疑.同时,β受体阻滞剂在AMI急性期的使用时期和剂量存在争议,在AMI后二级预防中的使用也与指南要求存在明显差距,我们对AMI后β受体阻滞剂的使用情况作一综述.

作者蒋桔泉丁世芳

机构地区中国人民解放军武汉总医院心血管内科

出处《临床内科杂志》 CAS 2017年第4期284-286,共3页 Journal of Clinical Internal Medicine

关键词急性心肌梗死 Β受体阻滞剂再灌注治疗溶栓经皮冠状动脉介入治疗

分类号 R541.61 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献3

1无.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2015,43(5):380-393. 被引量：2287
2中国第二项急性心肌梗死研究(摘要)[J].岭南心血管病杂志,2005,11(2):112-112. 被引量：3
3王丹宁,陈鹏飞,黄颖,陈侃,王磊,廖德宁.早期静脉应用β受体阻滞剂对急性心肌梗死患者预后影响的Meta分析[J].疑难病杂志,2015,14(5):511-515. 被引量：4

二级参考文献28

1Collaborative Research Group of Reperfusion Therapy in Acute Myocardial Infarction.重组葡激酶与重组组织型纤溶酶原激活剂治疗急性心肌梗死的随机多中心临床试验[J].中华心血管病杂志,2007,35(8):691-696. 被引量：43
2No authors Iisted. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. The Miami Trial Research Group [ J ]. Eur Heart J, 1985,6 ( 3 ) : 199-226.
3ISIS-1 collaborate group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1 [ J ]. Lan- cet, 1986,2 ( 8498 ) : 57-66.
4American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, O "gara PT, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [ J ]. J Am Call Cardiol,2013,61 (4) :e78-140.
5Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred be- ta-blockade following thrombolytic therapy in patients with acute myo- cardial infarction. Results of the Thrombolysis in Myocardial Infarction ( TIMI ) II-B Study [ J ]. Cilculation, 1991,83 ( 2 ) :422 -437.
6Pfisterer M, Cox JL, Granger CB,et al. Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experi- ence. Global Utilization of Streptokinase and TPA (alteplase) for Occlu- ded Coronary Arteries[J]. J Am Coil Cardiol,1998,32(3) :634-640.
7Harjai K J, Stone GW, Boura J, et al. Effects of prior beta-blocker therapy on clinical outcomes after primary coronary angioplasty for acute myocar- dial infarction[J]. Am J Cardiol,2003,91 (6) :655"660.
8Halkin A, Gfines CL, Cox DA, et al. Impact of intravenous beta-block- ade before primary angioplasty on survival in patients undergoing me- chanical reperfusion therapy for acute myocardial infarction [ J ]. J Am Coil Cardio1,2004,43 (10) : 1780-1787.
9Valle JA, Zhang M, Dixon S, et al. Impact of pre-proeedural beta block- ade on inpatient mortality in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction [ J ]. Am J Cardio1,2013 ,111 ( 12 ) : 171;4-1720.
10Hanada K, Higuma T, Nishizaki F, et al. Randomized study on the effi- cacy and safety of landiolol, an ultra-short-acting 131-adrenergic bloc- ker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention [ J ]. Circ J,2012,76 ( 2 ) :439-445.